Related Experiment Video
Updated: Jan 9, 2026

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
Regular use of pharmaceutical opioids and subsequent risk of cancer: a prospective cohort study and Mendelian
Mahdi Sheikh1, Allison Domingues1, Karine Alcala1
1Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
Background:
Opium consumption was classified as "carcinogenic to humans" by the International Agency for Research on Cancer (IARC). We investigated whether use of pharmaceutical opioids, derived from or synthesized to mimic opium, is associated with cancer risk using separate observational and genetic analyses.
Methods:
Observational analysis included 472,955 participants in the UK Biobank prospective cohort (2006-2022). Genetic analysis included 2-sample Mendelian Randomization (MR) analyses using data from 14 independent genome-wide-association-studies (N = 9931-357,292). Adjusted hazard ratios (a-HR) or odds ratios (ORs) associated with regular opioid use were assessed for six established opium-related cancers (lung, pancreatic, bladder, esophageal, oropharyngeal, and laryngeal) and seven non-opium-related cancers (prostate, breast, colon, endometrial, kidney, ovarian, and brain).
Findings:
In UK Biobank, regular opioid use was associated with increased risk of opium-related cancers among ever-smoking [a-HR = 1.33 (95% CI = 1.22-1.43)] and never-smoking participants [a-HR = 1.32 (1.10-1.59)], but not non-opium-related cancers [a-HR = 0.96 (0.91-1.02)]. Risk increased with opioid strength [a-HR = 1.30 (1.20-1.40) for weak opioids; a-HR = 1.86 (1.43-2.40) for strong opioids, p-trend < 0.0001] and duration of action [a-HR = 1.32 (1.22-1.42) for short-acting; a-HR = 1.65 (1.24-2.18) for long-acting opioids, p-trend < 0.0001]. Both observational and genetic analyses showed increased risks for most opium-related cancers, including lung [a-HR = 1.39 (1.27-1.53); MR-Odds Ratio (OR) = 1.17 (1.07-1.29)], pancreas [a-HR = 1.24 (1.01-1.52); MR-OR = 1.34 (1.11-1.62)], bladder [a-HR = 1.26 (1.02-1.56); MR-OR = 1.15 (1.03-1.29)], esophagus [a-HR = 1.18 (0.94-1.49); MR-OR = 1.24 (1.01-1.52)], and larynx [a-HR = 1.37 (0.85-2.20); MR-OR = 1.29 (1.04-1.61)]. Except for an inverse association with prostate cancer [a-HR = 0.83 (0.76-0.91); MR-OR = 0.99 (0.92-1.05)], associations were null for non-opium-related cancers.
Interpretation:
Regular use of pharmaceutical opioids was associated with elevated risk for cancers caused by opium, but not other cancers.
Funding:
US National Institutes of Health, French National Cancer Institute.
Related Concept Videos
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Mutagenicity and Carcinogenicity
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Prevention
Some...

